INTRODUCTION
Between 1980 and 1997, the number of twin births in the US increased by 52%. 1 This phenomenon is thought to be related to delayed childbearing as well as the more widespread use of assisted reproductive technologies (ART). The use of ART carries significant risk of inducing a multiple gestation. 2 Currently, 35% of all twin gestations, 59% to 77% of all triplet gestations, and 95% of all quadruplet gestations worldwide can be attributed to ART. 2 -4 The precipitous rise in the incidence of multiple gestations is a concern to both health care providers and payers, given the high rate of prematurity in this population and the associated costs of neonatal care. The presence of a multiple gestation categorically places a pregnancy at risk for maternal and neonatal complications. 5 In 1997, the incidence of preterm birth in twin gestations was 54.9%, and more than 55% of infants born in twin pregnancies were of low birth weight. 1 Despite advances in perinatal care, the rates of prematurity and low birth weight associated with a multiple gestation have steadily increased; the perinatal mortality rate in such pregnancies remains 3 to 10 times that of singleton pregnancy. 1, 6, 7 In addition, infants of multiple gestations have a higher risk of intrauterine growth restriction and an increase in medical problems associated with prematurity, frequently necessitating a neonatal intensive care unit (NICU) stay. 2, 4, 8 Economically, NICU stays are among the most expensive types of hospitalizations, resulting in a disproportionate contribution to perinatal health care costs. 9 Other authors have shown a dramatic difference in total hospital charges for multiple versus singleton deliveries; this difference is due primarily to increased neonatal, rather than maternal, charges. 2 The average charge per infant of a twin gestation is nearly double that of a singleton. Approximately 50% of this difference can be related to lower gestational age at delivery, and an additional 40% related to lower birth weight. 4 However, frequent or prolonged antepartum hospital admissions, often for preterm labor, also contribute significantly to the overall costs per pregnancy. Furthermore, the additional emotional and financial burden of family separation should not be minimized.
Whether preterm labor is an acute or chronic condition is a subject of disagreement among clinicians, though most will agree that the goal of early detection and treatment of preterm labor is later gestational age at delivery with a resultant increase in birth weight. A more mature neonate results in a lessened need for intensive
OBJECTIVE:
To compare the clinical and cost -effectiveness of treating recurrent preterm labor with continuous subcutaneous terbutaline versus oral tocolytics in twin gestations.
STUDY DESIGN:
In a retrospective, matched -cohort design, twin pregnancies treated as outpatients with continuous subcutaneous terbutaline were identified from a perinatal database, then matched 1:1 by gestational age at recurrent preterm labor to those receiving oral tocolytics. There were 353 patients per treatment group. A cost model was used to compare antepartum hospital, nursery, and outpatient charges.
RESULTS:
Infants of the subcutaneous terbutaline group had greater gestational age at delivery, higher birth weights, and less frequent neonatal intensive care unit admission. Charges for antepartum hospitalization and nursery were significantly less in the subcutaneous terbutaline group, while charges for outpatient services were less for the oral group. Mean total estimated charges were US$17,109 less for those receiving subcutaneous terbutaline.
CONCLUSION:
Improved clinical outcomes and decreased nursery utilization suggest costeffectiveness of outpatient continuous subcutaneous terbutaline versus oral tocolytics for the treatment of recurrent preterm labor. 
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intervention and a reduced incidence of the often-associated longterm sequelae. Once an initial episode of preterm labor is controlled, a treatment and management dilemma ensues for the health care provider due to its recurrent nature. Our goal was to evaluate the clinical and cost-effectiveness of using continuous subcutaneous terbutaline versus oral tocolysis to treat recurrent preterm labor in twin gestations.
MATERIALS AND METHODS
In a retrospective, matched-cohort design, we compared women with twin pregnancies hospitalized for recurrent preterm labor who were treated as outpatients with either continuous subcutaneous terbutaline or oral tocolysis, following stabilization of their acute condition. The two groups were matched for gestational age at recurrence of preterm labor. The study population was identified from women enrolled by their health care provider in a nationally available outpatient preterm labor identification program. This program included patient education regarding the signs and symptoms of preterm labor, home uterine activity monitoring, and daily telephonic nursing assessment of objective patient data and subjective symptoms. Upon enrolment, the patient diagnosis and treatment plan was obtained from the health care provider. Demographic, pregnancy history, and past and present medical condition data were collected from patient interview and the physician office record. The information collected was then entered into a computerized database. Informed consent for outpatient services and use of anonymous patient data for research purposes was obtained at initiation of treatment. While receiving outpatient services, data relating to current patient condition (monitored uterine activity, blood pressure and pulse, patient reported subjective symptoms, medications, hospital and office visits) were entered into the database during daily nursing contact. Pregnancy outcome data were collected after delivery. Periodic data validation occurred through a point-of-service chart review component of a comprehensive quality management program, and when data abstraction was performed.
Within this database, we identified 6545 women with twin gestations between January 1992 and July 1998. All patients experienced an initial episode of preterm labor as determined by their individual physician, which was treated with oral tocolysis. A total of 2161 were subsequently hospitalized for recurrence of preterm labor symptoms at less than 35 weeks' gestation. Following acute treatment on an inpatient basis, 1208 were stabilized and discharged to resume outpatient services. Of these, 505 were initiated on continuous subcutaneous terbutaline infusion, while 703 continued on oral tocolysis. The remaining women delivered, remained hospitalized, or were discharged from outpatient services. Using a random number table, those who received continuous subcutaneous terbutaline were matched 1:1 to those who received continued oral tocolysis by gestational age (days) at hospitalization for recurrent preterm labor. Those without a match were excluded.
The electronic outpatient database used in this study included dates of hospitalization and diagnosis; however, specific dose and type of parenteral tocolysis and cervical exams during hospitalization were not available for this analysis. Tocolytic dosage prescribed for oral or subcutaneous administration after hospital discharge and other patient management including antenatal testing, additional medications, recommended activity level, need for hospitalization, and timing of delivery were determined by the patients' health care provider.
Continuous subcutaneous terbutaline was administered via a portable microinfusion pump (MiniMed Technologies, Sylmar, CA, or Disetronics, Minneapolis, MN). The infusion device was programmed to deliver a continuous basal rate and intermittent bolus doses. The dosage schedule was based on each patient's uterine activity pattern, subjective symptoms, and body mass index. Those receiving continuous subcutaneous terbutaline received additional, individualized instruction relating to the device used, as well as infusion initiation technique, site selection and care, syringe change, and the procedure for administering an unscheduled (PRN) bolus per physician's order for increased uterine activity or persistent increase in preterm labor symptoms. Additionally, all patients, regardless of tocolytic administration route, were instructed on emergency procedures and appropriate reporting of adverse reactions related to medications and/or treatment.
To evaluate the cost-effectiveness of each treatment, a model was applied where charges incurred during the study period for antepartum hospitalization, outpatient services, and nursery days were standardized. In this model, maternal antepartum hospital days were estimated at US$1000/d, outpatient nursing services with continuous subcutaneous terbutaline at US$250/d, outpatient nursing services with oral tocolysis at US$70/d, normal newborn nursery at US$400/d, and NICU at US$2000/d. The estimated cost per day for hospital care combines accommodation and ancillary charges and does not take into account indirect costs. Physician charges and increased first-year and lifetime medical costs were not considered in the model. Parametric data were analyzed using Student's paired t, and nonparametric data were analyzed using Wilcoxon signed rank and McNemar's -squared analysis. Statistical significance was concluded for two-sided p values <.05.
RESULTS
A total of 353 women who received continuous subcutaneous terbutaline (SQT) were matched 1:1 to women who received oral tocolysis (PO) following stabilization of recurrent preterm labor. Maternal demographic and obstetric characteristics are presented in Table 1 . Overall, women receiving continuous subcutaneous terbutaline were slightly older, more likely to be married, and experienced their first preterm labor episode 1.4 days earlier than their oral tocolytic counterpart. Those receiving oral tocolytics were at a marginally increased risk due to a history of a prior preterm birth.
Continuous subcutaneous terbutaline was administered via a microinfusion pump, which delivered a low-dose basal rate and scheduled bolus doses. Overall, the mean continuous basal rate was 0.08±0.05 mg/hr. Women received an average of 8.0±2.7 boluses per 24-hour period, averaging 0.25 mg per bolus dose. Total amount of terbutaline given subcutaneously averaged 3.9±1.4 mg/d. In the oral tocolytic group, 92.3% received terbutaline, while the remainder received nifedipine, indomethacin, oral magnesium, or a combination thereof. Almost 10% of patients in the oral tocolytic group received concomitant tocolysis. Of those who received oral terbutaline, the average daily dose was 25.6±10.4 mg.
The mean gestational age at recurrent PTL was 31.3±2.3 weeks (matched variable). After recurrent PTL, women receiving subcutaneous terbutaline gained an average of 4.5 (95% confidence interval 2.3 to 6.8) more gestational days compared to their oral tocolytic counterpart. In the subcutaneous terbutaline group, 40.5% achieved at least 36 weeks' gestation, versus 30.3% of those receiving oral medication (p=.005). Prolongation of greater than 2 weeks occurred in 73.7% of the subcutaneous terbutaline group and in 59.2% of the oral tocolytic group.
The additional days gained by a higher percentage of women receiving subcutaneous terbutaline resulted in a later gestational age at delivery (Table 2 ). Figure 1 depicts the gestational age at delivery distribution for each study group. The subcutaneous terbutaline (SQT) curve shows a higher, narrower (kurtotic) peak occurring slightly later in gestation versus the shorter, wider curve for the oral tocolytic (PO) patients. Figure 1 . Gestational age at delivery.
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Neonatal outcomes are shown in Table 2 . Infants of women receiving subcutaneous terbutaline (SQT) weighed more at birth and had fewer nursery days. Overall, 30% fewer infants were admitted to the NICU from the subcutaneous terbutaline (SQT) group. For those admitted to the NICU, infants of the subcutaneous terbutaline (SQT) group had higher birth weights (2030±444 vs. 1933±465 g, p=.007), and shorter lengths of stay (17.3±16.1 vs. 20.8±17.4 days, p=.009) than infants admitted to the NICU from the oral tocolytic (PO) group.
There were a total of 19 perinatal losses, four in the subcutaneous terbutaline group and 15 in the oral tocolytic group ( p=.019).
Gestational ages at delivery for these losses ranged from 31.7 to 35.1 weeks and from 25.7 to 37.7 weeks for the SQT and PO groups, respectively. In the subcutaneous terbutaline group, three infants were stillborn and one died due to a congenital anomaly. In the oral tocolytic group, there were four stillborn infants and 11 neonatal deaths: three with fatal anomalies and eight died due to complications of prematurity. Reported maternal morbidities were few. One patient in the subcutaneous terbutaline group developed pulmonary edema during hospitalization for acute treatment of a subsequent episode of preterm labor. There were no maternal deaths in either group.
The three main components of estimated total pregnancy charges are shown in Table 3 . Both the estimated mean and median total cost for a twin pregnancy experiencing recurrent preterm labor were higher in those treated with oral tocolytics (PO). Nursery costs were the single largest contributor to total pregnancy costs for both groups. The second largest cost contributors were outpatient nursing costs for the subcutaneous terbutaline (SQT) group and antepartum hospital days for the oral tocolytic group. Following hospitalization and treatment for the recurrent preterm labor episode, which determined the patient group, those receiving continuous subcutaneous terbutaline required fewer hospital days than those receiving oral tocolysis (3.7±5.9 vs. 8.1±9.0 days, p<.001).
The sum of overall estimated charges is presented in Figure 2 . An estimated US$13.5 million was spent for outpatient nursing services, antepartum hospitalization, and newborn care for women in the subcutaneous terbutaline (SQT) group versus over US$19.5 million for the oral tocolytic (PO) group. Overall, in those treated with All data mean ± SD, unless otherwise specified. Data presented per total pregnancy. Nursery charge = US$0 for those with neonatal death. All data presented in US dollars. continuous subcutaneous terbutaline, mean estimated total charges were US$17,109 less per twin pregnancy.
DISCUSSION
The high rate of preterm birth in multiple gestations has many consequences, often including neonatal mortality, acute morbidity, and/or lifelong neurodevelopmental handicaps. Morbidity associated with preterm delivery results from the lack of full maturity of critical organ systems, most notably the respiratory, neurologic, and gastrointestinal systems. Immaturity in any or all of these systems places the infant at high risk and results in the need for prolonged and/or specialized medical care. 4 The sequelae of prematurity also have considerable short-term, as well as long-term, financial ramifications for both the parents and society as a whole.
Preterm labor, preterm rupture of membranes, intrauterine growth restriction, pre-eclampsia, and other pregnancy complications are more common in twin gestations than in singletons. 10 Tocolytic medications are widely used to treat the signs and symptoms of preterm labor. A rationale for using tocolytics is that prolongation of pregnancy equates to a greater gestational age at delivery and thus higher birth weight. This is of benefit to the infant as the risk of severe neonatal morbidity and mortality is reduced. Delaying delivery may allow for the natural developmental process to take place, the administration of corticosteroids to enhance fetal lung maturity, or can allow for in utero transfer to a facility better equipped to care for very preterm infants. Even a modest 48-to 72-hour prolongation of pregnancy may be greatly beneficial to improving neonatal outcomes and decreasing financial costs.
Our goal was to evaluate the clinical outcome and costeffectiveness of treating recurrent preterm labor with subcutaneous terbutaline versus oral tocolysis. In this study, we identified that infants of women treated with continuous subcutaneous terbutaline had better neonatal outcomes than those of women treated with oral tocolytics, and that this benefit of improved outcomes far outweighed the higher costs related to this outpatient treatment. We acknowledge that the retrospective, non-randomized design of this analysis, as well as the lack of a placebo control group, limits what may be concluded from our observations. However, it is also important to note that our focus was on treatments initiated after recurrence of preterm labor, and all women were hospitalized for acute treatment prior to the study period. These factors emphasize the acuity of the overall study population.
The cost data in this study were estimated for several reasons: the nationwide distribution of patients, the difficulty of obtaining actual charge data from inpatient facilities, and the 6-year study duration. Consequently, we felt it made for a better comparison to apply a cost model, which standardized charges across groups. A standardized model eliminates regional variations in charges, as well as equalizes the inflationary impact. In addition, we only analyzed charges occurring after recurrent preterm labor. Physician charges were not included in this analysis.
Our model is conservative in many aspects. Antepartum hospital costs were calculated at US$1000 per inpatient day. This is considerably less than other reports in the literature for antepartum hospitalization charges averaging approximately US$1400/d to US$2100/d, 11 -13 and government estimates provided by the Healthcare Cost and Utilization Project for 1994 (HCUP-3), which estimated nationwide inpatient charges for preterm labor at US$1621/d. 14 In determining antepartum charges, we did not include charges for hospital observation admissions of less than 24 hours, which may also decrease overall estimated charges for inpatient care.
Though actual charges may vary widely based on contractual arrangements, outpatient nursing services were estimated at US$250/d for those receiving continuous subcutaneous terbutaline, and US$70/d for those receiving oral terbutaline. The outpatient service fee included patient education materials, home nursing visits, daily telephonic assessment, durable medical equipment (uterine monitor for both groups, and microinfusion pump and supplies for the subcutaneous terbutaline group), and cost of tocolytic medication(s).
Data provided by HCUP-3 estimated a mean charge of US$2079/ d for infants with the diagnosis of low birth weight; US$2662/d for those with RDS; US$867/d for those born preterm, but not requiring intensive care; and US$515/d for normal newborn care. 14 In our model, costs for normal newborn nursery and NICU were conservatively estimated at US$400/d and US$2000/d, respectively. Further decreasing estimated nursery charges, we excluded from analysis those with neonatal death. This was necessary since exact length of nursery stay prior to death was not consistently documented; thus, all neonatal deaths were calculated at zero cost. We recognize that if these data had been available, the overall nursery costs would have increased, particularly in the oral tocolytic group. Median per-day charges for infants who die in the NICU are generally at least twice that of infants who are later discharged home or transferred to another facility. 15 Any uniform increase in the cost estimates used in our model would only exaggerate the differential savings achieved.
In this analysis, overall savings were realized through a reduction in NICU utilization and overall nursery days for infants of the subcutaneous terbutaline group. This is supported by previous work, which has shown substantial improvement in neonatal outcome and decreased costs related to higher birth weight and later gestational age at delivery. 4, 11 Though there appears to be savings in antepartum hospital charges for those receiving subcutaneous terbutaline, there was actually a cost shift to outpatient services. When combining mean charges for antepartum hospitalization and outpatient services, the total for each group is similar.
We believe that the greater prolongation of pregnancy and better neonatal outcomes achieved in our subcutaneous terbutaline study group were related to more precise dosing of terbutaline afforded by the programmable, automatic, microinfusion pump; there was a reduced incidence of myometrial desensitization (tachyphylaxis) and improved patient tolerance and compliance when terbutaline was administered subcutaneously. Our findings support previous investigations. 16 -18 The clinical efficacy and safety of terbutaline as a tocolytic have been studied, with varied results. While intravenous terbutaline has been shown to be effective in delaying delivery when used to treat an acute episode of preterm labor, 19 the need for prolonged use of tocolytics to maintain uterine quiescence continues to be studied. 20 -23 Nonetheless, many health care providers will continue to prescribe ongoing tocolysis after stabilization of acute preterm labor in an attempt to decrease the rate of recurrence and prolong pregnancy.
Oral terbutaline is frequently prescribed for ongoing tocolysis. Patient non-compliance is a frequent problem with oral terbutaline. Terbutaline has a relatively short half-life, and in the dosages required orally, cardiovascular side effects are often exhibited. This results in frequent dosing, sleep disruption, and patient discomfort related to common side effects, including tachycardia, headache, nausea, shakiness/tremors, and/or feelings of anxiety. The high doses required to maintain uterine quiescence often lead to desensitization of uterine beta receptors, resulting in tocolytic breakthrough and recurrent preterm labor.
In 1988, we first described our experience using a microinfusion pump to administer a low-dose basal rate and scheduled bolus doses of subcutaneous terbutaline on nine women with recurrent preterm labor. Pregnancies were prolonged an average of 9.2±4.3 weeks in this population. 23 In randomized fashion, we later reported on 68 patients who received either continuous subcutaneous terbutaline, or oral terbutaline, following stabilization with intravenous tocolysis. In this study, those receiving subcutaneous terbutaline had their pregnancies prolonged a mean of 8.6 weeks compared with a mean of 2.4 weeks in the oral terbutaline group. 24 Others have also compared continuous subcutaneous terbutaline to oral terbutaline for ongoing tocolysis following recurrent preterm labor. 18, 25 Allbert et al., 18 in a matched-study design, compared 32 patients who received subcutaneous terbutaline infusion to 32 patients who received oral therapy. He concluded that continuous subcutaneous terbutaline appeared to be more successful in prolonging gestation than oral therapy. Singleton and multiple gestations were combined. Women achieved 72% of desired prolongation with oral therapy compared to 86% desired prolongation for those receiving subcutaneous therapy. Lam et al., 25 in a recent twin study using a matched-cohort design with each patient serving as their own control, also compared gestational days gained with oral terbutaline to days gained with subcutaneous terbutaline. Women gained a mean of 19.3 days on oral terbutaline prior to recurrent preterm labor, with a subsequent mean gain of 34.0 days with continuous subcutaneous terbutaline.
The present study is the first of its kind to compare outcomes of twin pregnancies treated with subcutaneous terbutaline or oral tocolytics following recurrent preterm labor, and to examine estimated costs related to treatment and outcomes. As such, we demonstrated continuous subcutaneous terbutaline to be a costeffective treatment option in twin pregnancies experiencing recurrent preterm labor.
